RT info:eu-repo/semantics/article
T1 Combined concentrations and genetic variability of fibroblast growth factors predict cardiovascular risk in renal patients
A1 González-Rodríguez, Laura
A1 Martí-Antonio, Manuel
A1 Mota-Zamorano, Sonia
A1 Chicharro, Celia
A1 Cancho, Bárbara
A1 Álvarez, Álvaro
A1 Verde, Zoraida
A1 Fernández-Araque, Ana
A1 Bandrés, Fernando
A1 Robles, Nicolás Roberto
A1 Gervasini, Guillermo
AB Chronic kidney disease (CKD) is a major risk factor for cardiovascular events (CVE). We assessed whether circulating levels and genetic variability of endocrine fibroblast growth factors (FGF19, FGF21, and FGF23) could predict CV risk in these patients. In 1,182 participants (815 CKD patients and 367 controls), plasma FGF concentrations and 46 gene variants were analyzed, with participants followed-up for a mean of 37.6 ± 25.7 months for CVE. Clustering based on combined scores for all three FGF concentrations correlated strongly with CKD severity (p < 0.001) and predicted CVE after adjusting for other risk factors [hazard ratio (HR) = 2.03 (1.02–4.05), p = 0.044]. Four SNPs, notably FGF19 rs1307968 [odds ratio OR = 5.14 (1.53,17.27), p = 0.008], were also independently associated with CVE. Incorporating both combined FGF concentration scores and the relevant genetic variants into traditional risk models significantly improved prediction accuracy (AUC increased from 0.713 to 0.779; p < 0.0001). These findings suggest that combining FGF biomarkers with genetic information may enhance CV risk stratification in CKD patients.
PB ELSEVIER
SN 2589-0042
YR 2025
FD 2025-12-19
LK https://uvadoc.uva.es/handle/10324/81725
UL https://uvadoc.uva.es/handle/10324/81725
LA eng
NO iScience . 2025 Nov 19;28(12):114143.
DS UVaDOC
RD 17-ene-2026